These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628 [TBL] [Abstract][Full Text] [Related]
32. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives. Lee JA; Bubendorf L; Stahel R; Peters S Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353 [TBL] [Abstract][Full Text] [Related]
33. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861 [TBL] [Abstract][Full Text] [Related]
34. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. Roskoski R Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942 [TBL] [Abstract][Full Text] [Related]
35. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620 [TBL] [Abstract][Full Text] [Related]
36. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels. Duijkers FA; Gaal J; Meijerink JP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM Cell Oncol (Dordr); 2011 Oct; 34(5):409-17. PubMed ID: 21625996 [TBL] [Abstract][Full Text] [Related]
37. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711 [TBL] [Abstract][Full Text] [Related]
38. [Ceritinib in the treatment of an adult patient with advanced neuroblastoma positive to the somatic activating mutation of ALK F1174L.]. Soto Parra HJ; Noto L; Aiello MM Recenti Prog Med; 2020 Dec; 111(12):58e-62e. PubMed ID: 33362184 [TBL] [Abstract][Full Text] [Related]
39. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Siaw JT; Wan H; Pfeifer K; Rivera VM; Guan J; Palmer RH; Hallberg B Oncotarget; 2016 May; 7(20):29011-22. PubMed ID: 27049722 [TBL] [Abstract][Full Text] [Related]